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Background-—Functional cerebrovascular regulatory mechanisms are important for maintaining constant cerebral blood ﬂow and
oxygen supply in heathy individuals and are altered in heart failure. We aim to examine whether pulmonary arterial hypertension
(PAH) is associated with abnormal cerebrovascular regulation and lower cerebral oxygenation and their physiological and clinical
consequences.
Methods and Results-—Resting mean ﬂow velocity in the middle cerebral artery mean ﬂow velocity in the middle cerebral artery
(MCAvmean); transcranial Doppler), cerebral pressure-ﬂow relationship (assessed at rest and during squat-stand maneuvers;
analyzed using transfer function analysis), cerebrovascular reactivity to CO2, and central chemoreﬂex were assessed in 11 patients
with PAH and 11 matched healthy controls. Both groups also completed an incremental ramp exercise protocol until exhaustion,
during which MCAvmean, mean arterial pressure, cardiac output (photoplethysmography), end-tidal partial pressure of CO2, and
cerebral oxygenation (near-infrared spectroscopy) were measured. Patients were characterized by a signiﬁcant decrease in resting
MCAvmean (P<0.01) and higher transfer function gain at rest and during squat-stand maneuvers (both P<0.05). Cerebrovascular
reactivity to CO2 was reduced (P=0.03), whereas central chemoreceptor sensitivity was increased in PAH (P<0.01), the latter
correlating with increased resting ventilation (R2=0.47; P<0.05) and the exercise ventilation/CO2 production slope ( _VE= _VCO2
slope; R2=0.62; P<0.05) during exercise for patients. Exercise-induced increases in MCAvmean were limited in PAH (P<0.05).
Reduced MCAvmean contributed to impaired cerebral oxygen delivery and oxygenation (both P<0.05), the latter correlating with
exercise capacity in patients with PAH (R2=0.52; P=0.01).
Conclusions-—These ﬁndings provide comprehensive evidence for physiologically and clinically relevant impairments in cerebral
hemodynamic regulation and oxygenation in PAH. ( J Am Heart Assoc. 2017;6:e006126. DOI: 10.1161/JAHA.117.006126.)
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P ulmonary arterial hypertension (PAH) is characterized bydistal pulmonary artery remodeling and a progressively
failing right ventricle, resulting in poor exercise capacity.1
Modern therapies have reduced short-term mortality and
clinical worsening,2,3 despite only minimal long-term improve-
ment in survival and quality of life.4,5 A better assessment of
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the pathophysiological characteristics in PAH remains manda-
tory to address challenges in translating preclinical investiga-
tions into clinical trials and treatment.6 As such, mechanisms
involved in exercise intolerance remain incompletely under-
stood. They include cardiopulmonary hemodynamic impair-
ments and exercise-induced hypoxemia,7 as well as impaired
skeletal muscle function and morphological characteristics,8,9
oxygenation10 and angiogenesis.10,11 However, other mech-
anisms may also contribute to limit exercise and daily
activities in patients.
The regulation of cerebral blood ﬂow (CBF) is complex. Its
main determinants are blood pressure (BP) and the cerebral
pressure-ﬂow relationship, often termed cerebral autoregula-
tion. Other determinants include cardiac output (CO), arterial
blood gas, and autonomic nervous system and neurovascular
coupling for meeting local cerebral metabolic demand.12
Contemporary evidence demonstrates that CBF is reduced in
patients with mild to severe heart failure (HF),13,14 leading to
cognitive dysfunction, brain anatomical changes, and exercise
intolerance.15,16 Potential mechanisms involved in CBF reduc-
tion remain unclear, butmight be related to lowCO,17,18 lowered
cerebrovascular reactivity to CO2,
19,20 and an abnormal
regulation of the cerebral pressure-ﬂow relationship at rest21,22
or during posture change.18 Furthermore, in healthy individuals,
intense exercise leads to cerebral deoxygenation, mild cerebral
metabolic perturbation, and increased central fatigue in a
similar manner as exercise in hypoxia, suggesting that cerebral
oxygenation could affect exercise tolerance.23 Similarly,
reduced cerebral oxygenation per se has been demonstrated
as a limiting factor for exercise tolerance in patients with HF24
and type 2 diabetes mellitus,25 among others.
Several mechanisms that might alter CBF regulation have
been investigated in PAH over the years. As such, patients have
been characterized by impaired baroreﬂex sensitivity,26
increased sympathetic nerve trafﬁc,27 and hypocapnia.28
Recently, reduced cerebral oxygenation and its impact on
exercise capacity29 and reduced cerebrovascular reactivity to
CO2
30 have been documented in PAH, using near-infrared
spectroscopy; however, the associated integrative physiological
mechanisms were not thoroughly investigated. Therefore, the
aim of this study was to conduct a comprehensive assessment
of the cerebrovascular function in patients with PAH to
determine whether it is associated with abnormal cerebral
vascular regulation and oxygenation and their physiological and
clinical consequences. We hypothesized that patients with PAH
would exhibit a disproportionate decrease in CBF as a result of
vasoregulatory abnormalities. We also hypothesized that these
abnormalities would lead to decreased cerebral oxygenation
during exercise that would correlate with exercise tolerance.
Methods
Study Subjects
Eleven New York Heart Association functional class II to III
patients with idiopathic and heritable PAH were recruited.
PAH was deﬁned as mean pulmonary arterial pressure
≥25 mm Hg at rest, with a pulmonary capillary wedge
pressure ≤15 mm Hg, in agreement with the most recent
guideline.1 Only patients in stable condition during the past
4 months were eligible. Exclusion criteria were as follows: (1)
a 6-minute walked distance of <300 m; (2) left ventricular
ejection fraction <40%; (3) restrictive (lung ﬁbrosis on
computed tomography scan or total lung capacity <80% of
predicted) or obstructive (forced expiratory volume in the ﬁrst
second of expiration/forced vital capacity <70%) lung disease;
(4) body mass index >30 kg/m2; and (5) metabolic diseases
(eg, type 2 diabetes mellitus). Patients were individually
matched for age, sex, body weight, and height with 11 healthy
sedentary participants. All measurements were completed in
a thermoneutral exercise physiology laboratory over 2 visits,
separated by at least 48 hours (Figure S1). Participants were
instructed to abstain from exercise, alcohol and caffeine
consumption, and heavy meals in the 12 hours preceding
Clinical Perspective
What Is New?
• Patients with pulmonary arterial hypertension (PAH) have an
impaired cerebral pressure-ﬂow relationship, indicating that
changes in blood pressure are more passively transmitted to
the brain.
• Patients with PAH also have lower cerebrovascular reactivity
to CO2 and increased central chemoreceptor sensitivity, the
latter correlating with their exercise capacity.
• Patients exhibit marked impairments to cerebral blood ﬂow
and oxygenation during exercise, the latter tightly correlat-
ing with exercise capacity.
What Are the Clinical Implications?
• Impaired pressure-ﬂow relationship likely contributes to
presyncope symptoms and syncope in patients with PAH.
Practically, therapies lowering blood pressure should be
used cautiously in PAH, because brain perfusion is partic-
ularly sensitive to changes in blood pressure.
• Because cerebrovascular reactivity to CO2 is an important
determinant of cerebral blood ﬂow, its dysregulation might
contribute to decreasing cerebral blood ﬂow in PAH.
• Increased central chemoreceptor sensitivity contributes to
ventilatory abnormalities, resulting in increased resting
ventilation and ventilatory inefﬁciency during exercise.
• Exercise-induced cerebral hypoxia might result in premature
central fatigue and contribute to the multifaceted mecha-
nisms of exercise intolerance in PAH.
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each experimental testing. The institutional ethics committee
approved the research protocol (CER 20975), and all partic-
ipants gave written informed consent.
Study Protocol and Measurements
CBF and central hemodynamics
On visit 1, CBF was estimated by monitoring MCAvmean (mean
ﬂow velocity in the middle cerebral artery) with transcranial
Doppler ultrasonography (2.0-MHz probe; Doppler Box) using a
standardized searching method.31,32 After obtaining the opti-
mal signal/noise ratio, the probe was secured with a custom-
made headband and adhesive probe conductive ultrasonic gel
(Tensive). Cerebrovascular resistance index (mean arterial
pressure [MAP]/MCAvmean), cerebrovascular conductance
index (MCAvmean/MAP), and Gosling pulsatility index ([systolic
MCAvdiastolic MCAv]/MCAvmean) were calculated. A 3-lead
ECG was used for heart rate monitoring. BP was measured
noninvasively by ﬁnger photoplethysmography (Nexﬁn; BMEYE).
The cuff was positioned to the midphalanx of the middle ﬁnger
of the right hand and calibrated at heart level. CO was
determined by using a 3-element model of arterial input
impedance (Modelﬂow method). Systemic pulsatility index was
calculated as follows: (systolic APdiastolic AP)/MAP. Photo-
plethysmographic and transcranial Doppler ultrasonographic
data were simultaneously sampled at 1000 Hz via an analog-to-
digital converter (Powerlab 16/30) and stored on an external
disk for off-line computations (LabChart Pro version 7) (Data S1
provides further baseline analysis details).
Assessment and analysis of the cerebral pressure-ﬂow
relationship
Five minutes of spontaneous beat-to-beat BP and MCAv were
recorded in seated rest position for all participants, followed
by squat-stand maneuvers to enhance the linear interpretabil-
ity of the pressure-ﬂow metrics.33,34 All participants started in
a standing position, then squatted down until the back of their
legs attained a 90° angle. This position was maintained for a
speciﬁc period of time, after which they raised their legs. The
time periods for squat-stand maneuvers were as follows:
10-second squat, 10-second stand and 5-second squat, and
5-second stand (performed in a random order).
The analysis approach has been developed and validated in
previous studies.33–35 Brieﬂy, both BP and MCAv signals were
time-aligned using 250 milliseconds, associated with the BP
signal. Spontaneous (seated rest) and driven (squat-stand
maneuvers) beat-to-beat BP and MCAv signals were spline
interpolated and resampled at 4 Hz. Thereafter, transfer
function analysis was performed on the basis of the Welch
method. First, each high-pass ﬁltered signal was divided into 5
segments, with 50% overlap between consecutive segments.
Next, a Hanning window was applied to each data segment
before fast Fourier transform analysis. The linear transfer
function was derived as follows:
HPVðfÞ ¼ SPVðfÞSPPðfÞ (1)
where SPV is the cross-spectrum between BP and MCAv and
SPP is the autospectrum of BP. Spontaneous BP, MCAv
spectral power, and the mean value of transfer function
coherence, phase, and gain were calculated in the high
frequency (0.20–0.40 Hz), low frequency (LF; 0.07–0.20 Hz),
and very-low frequency (VLF; 0.02–0.07 Hz) ranges, as
previously deﬁned.34 Previous studies have shown that
transfer function gain may exhibit different dynamics,
depending on whether the underlying time series are normal-
ized.36,37 Therefore, transfer function gain was assessed as
normalized units (nGain; %/%) to account for the intersubject
variability. For spontaneous data, the transfer function
parameters were band averaged across the VLF, LF, and
high-frequency ranges, but driven BP oscillations were
sampled at the point estimate of the driven frequency
(0.05 Hz corresponding to 10-second squat and 10-second
stand, and 0.10 Hz corresponding to 5-second squat and
5-second stand). These point estimates were selected
because they are in the VLF (0.02–0.07 Hz) and LF (0.07–
0.20 Hz) ranges, where cerebral pressure-ﬂow regulation is
thought to be most operant.33–35 Coherence quantiﬁes to
what extent changes in MCAv are linearly related with BP,
whereas phase quantiﬁes the temporal alignment between BP
relative to MCAv.33,34 The gain quantiﬁes the effective
amplitude dampening of BP ﬂuctuations.33,34 Only the trans-
fer function analysis phase and gain values, where coherence
>0.5, were included in analysis to ensure data robustness.38
All data were analyzed with a custom-designed software in
LabVIEW 2011. Respiratory gases and ventilation (Ultima
CardiO2 gas exchange analysis system) were monitored to
ensure normal breathing in participants.
Cerebrovascular reactivity to CO2 and central
chemoreceptor sensitivity assessment
Both groups performed a modiﬁed rebreathing protocol.39,40
Participants were seated comfortably and ﬁtted with a
mouthpiece connected to a pneumotach for respiratory gas
analysis and a 2-way valve that allowed switching from room
air to a 5-L rebreathing bag. The test consisted in 3 phases:
(1) baseline (breathing room air); (2) hyperventilation to a
target end-tidal partial pressure of CO2 (PETCO2) between 20
and 25 mm Hg for 1 minute; and (3) dynamic rebreathing,
during which participants were switched to the rebreathing
bag with a gas mixture containing 7% CO2 and 93% O2 and
breathed normally until the PETCO2 was >60 mm Hg,
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ventilation exceeded 100 L/min, or discomfort occurred. The
cerebrovascular reactivity to CO2 was determined using the
linear regression of relative change (D) in MCAvmean against
the PETCO2. Both Dcerebrovascular conductance index-
PETCO2 and DMAP-PETCO2 slopes were also assessed. A
single line was ﬁtted in the most linear part of the rebreathing
phase to best exclude pressure-passive cerebral perfusion
occurring after maximal vasodilatation. The central chemore-
ceptor sensitivity was determined by ﬁrst plotting the minute
ventilation ( _VE) and PETCO2 to identify the _VE breakpoint
(taken as the operating threshold of the central chemorecep-
tors) and then determined as the slope of a linear regression
applied to the _VE against the PETCO2 after the breakpoint
(Data S1).
Incremental exercise test
On visit 2, a cardiopulmonary exercise test was performed on an
electromagnetically braked cycle ergometer, according to
current recommendations.41 After a 5-minute rest and1 minute
of unloaded pedaling, participants exercised using an individ-
ualized incremental ramp protocol (5–25 W/min) until voli-
tional exhaustion. Heart rate, BP, breath-by-breath analysis of
respired gas, pulse oximetry, CO, and MCAvmean were contin-
uously monitored, as previously described. Changes in cerebral
oxygen delivery from baseline during exercise were estimated
according to the following formula: DcDO2=DMCAvmean9arte-
rial oxygen content (estimated as 1.349hemoglobin9Dpulse
oximetry). Exercise data from Nexﬁn and transcranial Doppler
ultrasonography were resampled at 1 Hz and time aligned with
breath-by-breathmeasurements. Data were then averaged over
a minimum of 5 cardiac cycles and compared for relative
workloads throughout the test.
Cerebral capillary oxygen saturation during exercise
Cerebral oxygenation was monitored by near-infrared spec-
troscopy (Oxiplex TS) in the prefrontal cortex capillary bed
(Data S1). Relative changes from baseline in cerebral
oxygenated, deoxygenated, and total hemoglobin concentra-
tion were measured.10 Cerebral oxygenation saturation was
evaluated using the cerebral oxygenated hemoglobin/cerebral
total hemoglobin ratio, whereas change in cerebral deoxy-
genated hemoglobin was used as a surrogate of the local
oxygen delivery and use matching.
Statistical Analysis
Data are reported as meanSD, unless otherwise speciﬁed.
An unpaired t test was used to compare both groups at
baseline when data were normally distributed (D’Agostino-
Pearson omnibus normality test and assessment of the SD).
When not normally distributed, data were transformed using
log10. Unpaired t tests were then applied to the transformed
data. For exercise data, a 2-way repeated-measures ANOVA
was used. After an interaction effect (exercise inten-
sity9groups), differences were located using paired (within-
group) and independent (between-group) samples t tests, with
Bonferroni correction. The Pearson correlation coefﬁcient was
used to evaluate the relationship between cerebral oxygena-
tion saturation and change in cerebral deoxygenated
hemoglobin and exercise capacity, deﬁned as the percentage
of predicted peak oxygen consumption ( _VO2peak % pre-
dicted). P<0.05 was considered statistically signiﬁcant. Data
were analyzed using GraphPad Prism version 6.0h for Mac.
Results
Patients With PAH Displayed Lower CBF at Rest
Baseline characteristics and exercise capacity variables in
patients with PAH and controls are presented in Table.
Resting MCAv (systolic, diastolic, and MCAvmean; Figure 1A
through 1C) was reduced in patients with PAH compared with
controls, resulting in an increased Gosling pulsatility index
(Figure 1D). Conversely, no differences in cerebrovascular
conductance index and cerebrovascular resistance index were
observed (Figure 1E and 1F).
PAH Is Characterized by Abnormal Cerebral
Pressure-Flow Relationship
The spectral power of BP variability was decreased by 75% in
patients with PAH during spontaneous oscillations in the LF
range (0.07–0.20 Hz), whereas MCAv variability, coherence,
and phase were similar between groups. However, nGain
was increased by 21% in the LF range for patients (Figure 2).
For driven oscillations, spectral power for BP and MCAv was
lower in patients with PAH for both VLF and LF (Figure 3A
through 3D). Transfer function analysis revealed similar
coherence and higher phase shift for both frequencies;
nGain was higher only in LF in patients with PAH (Figure 3E
through 3G). Representative traces for 1 patient with PAH
and 1 healthy control are shown in Figures S2 and S3.
Ventilatory responses during driven oscillation assessment
are presented in Table S1.
Lower Cerebrovascular CO2 Reactivity and
Increased Central Chemoreceptor Sensitivity to
CO2 in Patients With PAH
In patients, the cerebrovascular reactivity to CO2 was
signiﬁcantly reduced, with a 58% and 78% decrease in the
MCAv-PETCO2 slope (Figure 4A) and cerebrovascular conduc-
tance index-PETCO2 slope (Figure 4B), respectively.
DOI: 10.1161/JAHA.117.006126 Journal of the American Heart Association 4
Altered Cerebral Regulation and Oxygenation in PAH Malenfant et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on N
ovem
ber 21, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Cerebrovascular reactivity to CO2 was independent from MAP
(Figure 4C). Hence, hyperventilation did not fully account for
decreased CBF in patients with PAH because CBF was
reduced for any given PETCO2 value (Figure S4). Moreover,
PAH was also associated with a 58% increase in central
chemoreceptor sensitivity compared with controls (Fig-
ure 4D), which correlated with minute ventilation at rest
(Figure 4E) and exercise _VE= _VCO2 slope in patients with PAH
(Figure 4F).
Patients With PAH Displayed Lower MCAvmean
and Cerebral Oxygenation During Exercise,
Contributing to Exercise Intolerance
Patients with PAH displayed lower MCAvmean compared with
controls throughout exercise (Figure 5A). Increases in CO and
minute ventilation during exercise were comparable between
groups, but MAP remained lower in patients compared with
controls (Figure 5B through 5D). Patients with PAH also
displayed a higher _VE= _VCO2 ratio and a lower PETCO2
throughout exercise (Figure 5E and 5F).
Exploration of potential mechanisms driving CBF revealed
that exercise-induced changes in MCAvmean in control
subjects tightly correlated with changes in PETCO2 (r=0.79;
P=0.004), whereas it did not correlate with changes in MAP
(r=0.36; P=0.35). Contrary to controls, in patients, exercise-
induced changes in MCAvmean tightly correlated with changes
Table. Baseline Characteristics and Exercise Capacity
Characteristics
PAH Group
(n=11)
Control Group
(n=11)
Demographics
Sex, F/M ratio 8:3 8:3
Age, y 44 (12) 43 (15)
BMI, kg/m2 25 (5) 25 (3)
PAH subtype
iPAH/PAH-Her ratio 9:2 NA
WHO functional class
II/III 8:3 NA
Resting pulmonary hemodynamic
mPAP, mm Hg 49 (10) NA
CI, L/min per m 3.2 (0.8) NA
PVR, dyne/s per cm5 547 (172) NA
PAOP, mm Hg 10 (3) NA
SvO2, % 71 (5) NA
Medical treatment with PAH-targeted agents
Agents
Prostacyclin analogue 2 NA
PDE-5i 9 NA
ERA 6 NA
Monotherapy 5 NA
Combination therapy 6 NA
Blood sampling
Hemoglobin, g/L (PAH group,
n=10; control group, n=11)
149 (15) 141 (15)
Hematocrit (PAH
group, n=8;
control group, n=6)
0.42 (0.03) 0.41 (0.03)
Rest hemodynamic and ventilation
sAP, mm Hg 120 (21) 129 (11)
dAP, mm Hg 71 (12) 78 (7)
MAP, mm Hg 87 (14) 95 (7)
Systemic pulsatility index 0.561 (0.132) 0.537 (0.085)
HR, bpm 67 (14) 71 (9)
SpO2, % 97 (2) 99 (1)*
PETCO2, mm Hg 33 (4) 39 (5)
†
VE, L/min (PAH group,
n=10; control group,
n=11)
14 (2) 10 (2)‡
Exercise capacity
6-Min walk test
Distance, m 494 (93) NA
% Predicted, % 85 (22) NA
Continued
Table. Continued
Characteristics
PAH Group
(n=11)
Control Group
(n=11)
CPET
Work rate, W 86 (34) 163 (54)‡
Peak _VO2, mLO2/min per kg 17.2 (4.0) 29.1 (5.7)
§
Peak _VO2 (% predicted) 67 (18) 110 (16)
§
Anaerobic threshold, % 45 (11) 61 (12)†
_VE= _VCO2 slope 49 (15) 28 (5)
§
End-exercise Borg dyspnea 7.9 (1.5) 7.8 (1.4)
Data are presented as mean (SD) unless otherwise indicated. Anaerobic threshold was
determined using the V-slope method. BMI indicates body mass index; bpm, beats per
minute; CI, cardiac index; CPET, cardiopulmonary exercise testing; dAP, diastolic arterial
pressure; ERA, endothelin receptor antagonist; F, female; HR, heart rate; iPAH, idiopathic
PAH; M, male; MAP, mean arterial pressure; mPAP, mean pulmonary arterial pressure;
NA, not applicable; PAH, pulmonary arterial hypertension; PAH-Her, heritable PAH; PAOP,
pulmonary arterial occlusion pressure; PDE-5i, phosphodiesterase type 5 inhibitor;
PETCO2, end-tidal CO2 pressure; PVR, pulmonary vascular resistance; sAP, systolic
arterial pressure; SpO2, systemic oxygen saturation; SvO2, systemic venous oxygen
saturation; VE, minute ventilation; VE/VCO2 slope, relationship between VE and volume of
expired CO2; and WHO, World Health Organization.
*P<0.05.
†P<0.01.
‡P<0.001.
§P<0.0001.
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in MAP (r=0.78; P=0.01), being consistent with the abnormal
cerebral pressure-ﬂow relationship previously observed. Con-
versely, exercise-induced changes in MCAvmean did not
correlate with PETCO2 (r=0.42; P=0.19). Overall, these
ﬁndings suggest that physiological mechanisms driving exer-
cise-induced changes in MCAvmean differ between groups.
In addition to reduced MCAvmean, patients with PAH had
exercise-induced systemic oxygen desaturation (Figure 6A),
contributing to decreased estimated cerebral oxygen delivery
(Figure 6B). This ﬁnding resulted in markedly impaired
cerebral oxygenation in PAH during exercise, beginning in
the early stages of exercise (Figure 6C and 6D). End-exercise
attenuated cerebral oxygenation saturation and end-exercise
increased change in cerebral deoxygenated hemoglobin
correlated with exercise capacity in patients with PAH only
(Figure 6E and 6F).
Discussion
This study provides several new ﬁndings on cerebrovascular
regulation and its impacts in PAH. We demonstrated that
patients with PAH have a lower CBF at rest and during
exercise, likely related to alterations in the cerebral pressure-
ﬂow relationship at rest and to lower systemic BP, throughout
exercise. We also demonstrated that patients with PAH have a
lower cerebrovascular reactivity to CO2 and increased central
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Figure 1. Resting cerebral blood ﬂow (CBF) is reduced in patients with pulmonary arterial hypertension (PAH) compared with controls (Ctrls).
Patients with PAH (open circles) exhibited lower resting CBF compared with Ctrls (closed circles), as assessed using systolic (P=0.08) (A),
diastolic (P=0.002) (B), and mean ﬂow velocity in the middle cerebral artery (MCAvmean; P=0.004) (C). Consequently, patients with PAH exhibited
increased Gosling pulsatility index (D), whereas cerebrovascular conductance index (CVCi; P=0.27) (E) and cerebrovascular resistance index
(CVRi; P=0.25) (F) were similar. dMCAv indicates diastolic middle cerebral artery blood ﬂow velocity; and sMCAv, systolic middle cerebral artery
blood ﬂow velocity.
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chemoreceptor sensitivity that might further decrease brain
perfusion. Ultimately, patients with PAH exhibit marked
impairments in cerebral oxygenation, which tightly correlate
with their exercise capacity.
Impaired Cerebral Pressure-Flow Relationship in
PAH
Under both spontaneous and driven oscillations, patients had
decreased BP and MCAv variability. Both metrics are impor-
tant determinants of orthostatic tolerance. Indeed, main-
tained and even increased BP and MCAv variability have
protected cerebral perfusion under experimental hypotension
generated via low body negative pressure.42 Nitric oxide
release through increased cerebral shear stress has been
suggested as one potential regulatory mechanism.43 Inter-
estingly, in addition to shear stress, exercise strongly
promotes intravascular nitric oxide metabolite formation in
healthy individuals, demonstrating that it accounts as an
important mechanism for coupling oxygen delivery and
metabolic demand.44 Patients with PAH are well known for
decreased nitric oxide synthesis, among other altered
endothelium-dependent vasodilators.45 Whether these alter-
ations are also present in the cerebral vasculature of patients
with PAH remains to be determined.
Under driven oscillations, patients with PAH have
increased phase and nGain, altogether exhibiting alterations
in the cerebral pressure-ﬂow relationship. However, in
healthy individuals, an impaired cerebral pressure-ﬂow
relationship is usually apparent through decreased phase
and concomitant increased nGain.33,34 Therefore, the pre-
sent study revealed contrasting results under driven oscil-
lations for the phase and nGain for patients with PAH. The
phase was increased in both VLF and LF, whereas nGain was
increased only in LF. One hypothesis might explain those
results. The pronounced hypocapnic state and the increased
demand on the respiratory system observed in patients may
have contributed to the increased phase. Indeed, increased
respiratory demand and acute hypocapnia both contribute to
an increased phase in healthy young trained cyclists,46
whereas hypocapnia occurring after the administration of
endotoxin to healthy individuals was also associated with an
increased phase.47 The mechanisms altering the pressure-
ﬂow relationship are not well deﬁned. However, one recent
investigation in HF demonstrated that an increased cerebral
microvascular tone, driven primarily through the tumor
necrosis factor-/ that activates the sphingosine kinase 1/
sphingosine-1-phosphate signaling pathway, accounts as one
mechanism altering this relationship.48 Interestingly, both
elevated circulating proinﬂammatory cytokines and sphin-
gosine kinase 1 and sphingosine-1-phosphate have been
implicated in the characteristic proproliferative,
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antiapoptotic, and vasoconstrictive phenotype of PAH.49–51
The potential implication of this pathway in the altered
cerebrovascular regulation in PAH remains to be investi-
gated.
Impaired Cerebrovascular Reactivity to CO2 and
Central Chemosensitivity in PAH
Cerebrovascular reactivity to CO2 and cerebral pressure-ﬂow
relationship are important determinant of CBF regulation, but
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controlled through different mechanisms.36,52 CO2 modulates
CBF via a direct effect of extracellular pH on the smooth muscle
cells of small pial arterioles, in addition to other neural, humoral,
and physical factors.12 Hence, an increase in CO2 leads to
acidosis that decreases vascular smooth muscle cells’ tone
through activation of potassium (K+) channels,52 including the
ATP-sensitive K+ channels, voltage-gated K+ channels, and 2-
pore domain weakly inward rectifying (TWIK)-related acid
sensitive (TASK-1) K+ channelfamily member,53 resulting in
increased CBF. Interestingly, several voltage-gated K+ channel
expressions, including TASK-1 expression, are decreased in the
lungs of patients with PAH.54,55 Whether those defects are
limited to the lungs remains elusive.
Recently, Vicenzi et al indirectly measured increased
central chemosensitivity in PAH, based on the method of
Naeije and van de Borne,56 by plotting the exercise ventilatory
equivalent for CO2 ( _VE= _VCO2) against PETCO2, suggesting it
might play a role in the wasted ventilation.57 The present
study directly assessed central chemoreceptor sensitivity and
demonstrates its increase in PAH as well. Dyspnea is
traditionally associated with ventilatory abnormalities, char-
acterized by higher ventilatory demand, dynamic hyperinﬂa-
tion, and a rapid, shallow breath frequency, especially in
patients with severe PAH.58,59 When compared with HF,
patients with PAH have similar exercise intolerance, but are
more dyspneic in relation to reduced ventilatory efﬁciency.60
Therefore, the present data add to the current literature on
dyspnea in PAH, because increased central chemoreceptor
sensitivity contributes to increased resting ventilation and
increased ventilatory inefﬁciency during exercise. Hence, as
suggested by Vicenzi et al, increased chemosensitivity is an
important mechanism in wasted ventilation for patients.57
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Indeed, the cerebrovascular reactivity to CO2 ultimately
serves to keep central pH relatively constant, washing out
brain stem CO2 through vasodilation. In this context, a
blunted cerebrovascular reactivity to CO2 might protect the
patients’ brain from further decrease in perfusion, but might
also add to the stimulation of the central chemoreﬂex by
preventing adequate CO2 washout from the brain stem.
Cerebral Oxygenation
Although brain oxygen demand increases with exercise, brain
oxygenation is only secured by enhancing perfusion or oxygen
extraction. In the present study, cerebral capillary oxygen
saturation was assessed noninvasively using near-infrared
spectroscopy, which has adequately tracked changes in
jugular bulb saturation.61 In PAH, cerebral oxygenation was
markedly impaired during the early stages of exercise and
persisted until exhaustion as a result of both exercise-induced
systemic desaturation and reduced CBF. Impaired cerebral
oxygenation also strongly correlated with exercise capacity in
PAH, as did skeletal muscle oxygenation.10 Therefore, this
ﬁnding supports that cerebral oxygenation is critical for
exercise in patients. However, whether cerebral oxygenation
speciﬁcally inﬂuences exercise tolerance in PAH per se, or
simply reﬂects global impairment in oxygen transport and use,
remains to be determined.
Clinical Consequences
Impaired cerebral pressure-ﬂow relationship indicates that
changes in BP are more passively transmitted to the brain in
PAH and are likely to explain why patients are less tolerant to
presyncope symptoms and more prone to syncope after
Valsalva-induced decreases in BP.62 Pharmacological treat-
ment plans should take into consideration that brain perfusion
is particularly sensitive to BP impairments in patients with
PAH. Exercise-induced cerebral hypoxia might lead to a shift
toward nonoxidative metabolization of lactate and glucose, in
a similar manner as short-term altitude exposure in healthy
individuals,63 increasing central fatigue64 and contributing to
early exercise termination. Prevalent mental disturbance has
been associated with HF, including multiple brain anatomical
and cognitive changes.15,65,66 Different investigators consid-
ered that impaired CBF might be one contributing factor.66,67
Therefore, the impact of cerebral hypoxemia, potential brain
anatomical dysfunction, and cognitive dysfunction could be
present in PAH and needs further investigations.
Methodological Limitations
First, we acknowledge that the limited sample size and the
multiple statistical analyses might have led to type I errors.
However, our sample size was calculated a priori and was
comparable to similar studies in PAH. More important, all
physiological observations were consistent with impairments in
cerebral hemodynamic regulation and oxygenation in PAH,
reinforcing the external validity of our ﬁndings. Also, the skull is
an obstacle to the penetration of ultrasound waves because the
bone strongly attenuates their resolution, makingmeasurement
of vessel luminal diameter not possiblewith transcranial Doppler
ultrasonography.32 The validity of MCAvmean as a surrogate of
CBF assumes a constant diameter of the insonated vessel.31
This assumption has been valid with arterial blood gas
changes.68,69 However, it remains possible that diameter
changes occur in similar condition.70,71 In the present study,
the lower PETCO2 in PAH would tend to reduce the MCA
diameter, overestimating CBF and thus minimizing differences
between PAH and controls. Second, squat-standmaneuvers can
be considered as aerobic exercise. Thus, these maneuvers may
modulate the dynamic pressure-ﬂow relationship of the cerebral
circulation by increasing regional brain activation and, more
systemically, resulting in autonomic and humoral changes that
may modulate CBF, especially in patients with PAH. The impact
of brain activation during the squat-stand maneuvers on both
phase and nGain should be minimal because moderate- and
high-intensity aerobic exercise does not alter cerebral pressure-
ﬂow relationship.72 Transfer function analysis metrics rely on a
linearmathematical approach to interpret the linear relationship
between BP and CBF. However, recent studies suggest that
other dynamic mechanisms, such as cerebral vessel compli-
ance, might play a role in dampening BP ﬂuctuations, the latter
being nonlinear.73 Therefore, these results cannot be inter-
preted as measures of cerebral autoregulation per se.
Likewise to consider, acute severe hypoxia may limit the
extent of CO2-mediated vasoconstriction through blunted cere-
brovascular reactivity to CO2 to preserve CBF andmetabolism.
74
This could have minimized the differences in CBF observed
between patients with PAH and controls. However, most of our
patients had normal or near-normal systemic oxygenation at
rest. Therefore, hypoxic effect on the response of CBF to CO2 is
likely negligible. Also, we acknowledge that hypocapnia and
lactic acid accumulation at the early stage of exercise could have
resulted in a leftward and a rightward shift of the hemoglobin
dissociation curve, respectively, modulating O2 afﬁnity to
hemoglobin and potentially adding to the burden of lower
cerebral oxygen delivery and oxygenation. Finally, both iloprost
and sildenaﬁl only minimally inﬂuence short-term ﬂow velocity in
the posterior cerebral artery in PAH.75 Nevertheless, a potential
inﬂuence of the PAH therapies cannot be excluded.
Conclusion
The present study provides evidence that patients with PAH
have functional cerebrovascular abnormalities, including an
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impaired cerebral pressure-ﬂow relationship and a blunted
cerebrovascular reactivity to CO2. Patients with PAH also
exhibit enhanced chemoreceptor sensitivity in relation to
excessive ventilation at rest and effort. During exercise, these
functional abnormalities are also present and contribute, in
addition to exercise-induced hypoxemia, to impair cerebral
oxygenation, which correlates with exercise capacity in PAH.
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 Data S1. 
 
Supplemental Methods 
 
Measurements  
Cerebral capillary oxygen saturation. Cerebral oxygenation was monitored by near-
infrared spectroscopy (NIRS) using a single-distance, continuous wave light, dual-channel 
Oxiplex TS (ISS, Champlain, IL, USA). This system exploits the difference in optical absorption 
spectra between the oxygenated and the deoxygenated state of the hemoglobin in small vessels 
<200 m, providing an estimated capillary O2 saturation. The NIRS fiber optode consisted of 
eight light-emitting diodes operating at wavelengths of 690 and 830 nm and one detector with a 
separated distance of approximately 4 cm, corresponding to a light penetration depth of 2 cm in 
the brain tissue. The signal was analyzed using the modified Beer-Lambert law. Before 
placements, the NIRS system was calibrated using calibration block of known density. Values 
reported for cerebral oxygenation account predominantly for hemoglobin oxygenation in the pre-
frontal cortex. The NIRS probe was attached as high as possible on the left forehead to avoid the 
frontal sinuses, and was covered by a black bathing cap and the headband for protection from 
external light and to limit probe movements.  
 
Data Analysis 
Baseline analysis. Baseline cerebral and central hemodynamics were both calculated as 
the average of the last stable minute of the seated resting period for day 1 and before CPET. 
Nexfin has shown reliably to assess the dynamic changes in beat-to-beat BP and cardiac output 1, 
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 2. The Nexfin use has also been validated against intra-aortic BP measurements for frequency-
domain patterns for coherence, phase and gain response 3. 
 
Absolute cerebrovascular reactivity to CO2 Analysis. The cerebrovascular reactivity to 
CO2 was also determined using absolute MCAvmean (cm/s). MCAvmean and PETCO2 were pooled 
using a method for averaging the individual response curves, thereby minimizing intersubject 
variability while preserving intrinsic linearity 4. Data from the last minute of the baseline phase, 
the last 30 sec of the hyperventilation phase and the rebreathing phase, one minute after 
switching to the rebreathing bag, were used. Linear regression was then used to obtain the slope 
of the pooled MCAvmean vs. PETCO2 relationship. Data are presented in Figure S4. 
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 Table S1. Ventilatory responses during rest and the squat-stand manoeuvres 
 PAH Ctrls p-Value 
Seated Rest n=10 n=11  
VE (L/min) 11 (3) 8 (2) 0.01 
RR (Br/min) 17 (4) 12 (3) <0.01 
VT (L) 0.67 (0.14) 0.66 (0.12) 0.91 
End-tidal CO2 (mmHg) 32 (5) 41 (5) <0.01 
CV End-tidal CO2 (%) 3.2 (0.9) 3.2 (0.9) 0.99 
Repeated squat-stand maneuvers (0.05 Hz)  n=10 n=11  
VE (L/min) 16 (2) 12 (2) <0.01 
RR (Br/min) 21 (5) 17 (3) 0.02 
VT (L) 0.84 (0.37) 0.75 (0.10) 0.58 
End-tidal CO2 (mmHg) 32 (4) 42 (6) <0.01 
CV End-tidal CO2 (%) 3.5 (0.9) 5.3 (1.5) <0.01 
Repeated squat-stand maneuvers (0.10 Hz) n=9 n=11  
VE (L/min) 17 (3) 13 (2) <0.01 
RR (Br/min) 22 (5) 17 (3) <0.01 
VT (L) 0.84 (0.29) 0.79 (0.09) 0.60 
End-tidal CO2 (mmHg) 33 (4) 42 (6) <0.01 
CV End-tidal CO2 (%) 3.8 (2.1) 5.6 (1.6) 0.04 
Data are presented as mean (standard deviation). Abbreviations are VE: minute ventilation; RR respiratory rate; VT: 
tidal volume; CV: coefficient of variation. 
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 Figure S1. Experimental protocol. 
 
 
 
 
 
 
 
 
 
 
 
VISIT 1
VISIT 2
Seated rest
Cerebral pressure-flow 
relationship
Modified rebreathing protocol
5 min rest
Baseline Cerebral 
blood flow 
measurements
(Figure 1)
Spontaneous 
pressure-flow 
relationship
(Figure 2)
Squat-Stand manoeuvers
5 min rest
Driven pressure-flow 
relationship
(Figure 3)
Cerebrovascular Reactivity to CO2
MCAvmean – PETCO2 Slope
(Figure 4)
Central chemoreceptor sensitivity
VE – PETCO2 Slope
(Figure 4)
Incremental exercise test
Exercise cerebral blood flow, central 
hemodynamic and ventilation
(Figure 5)
Exercise cerebral oxygen saturation and 
exercise tolerance
(Figure 6)
4
8
 h
rs
. 
re
s
t 
p
e
ri
o
d
 by guest on N
ovem
ber 21, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
 Figure S2. Representative resting trace. 
 
Data from one control subject and one PAH patient showing beat-by-beat variability in MCAv 
and BP in the time domain for the seating rest period of 5 minutes. Abbreviations are: MCAv: 
middle cereal artery velocity; BP: blood pressure; Ctrl: control; PAH: pulmonary arterial 
hypertension.  
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 Figure S3. Representative squat-stand trace. 
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 Data from one control subject and one PAH patient showing beat-by-beat variability in MCAv 
and BP in the time domain for the squat-stand maneuvers driven oscillations at 0.05 Hz and 0.1 
Hz. Abbreviations are: MCAv: middle cereal artery velocity; BP: blood pressure; Ctrl: control; 
PAH: pulmonary arterial hypertension.  
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 Figure S4. Absolute cerebrovascular reactivity to CO2. 
 
Poon-adjusted 4 absolute cerebrovascular reactivity to CO2 analysis demonstrated that PAH 
patients (open circles) had blunted reactivity, as MCAv being consistently lower at iso-PETCO2 
throughout the physiologic range of PETCO2 (0.91 (0.06) vs 1.66 (0.03) cm/s/mmHg; p<0.0001), 
compared to controls (closed circles). Abbreviations are: MCAv: middle cerebral artery velocity; 
PETCO2: end-tidal CO2 partial pressure.  
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